A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

• Drug: AZD6750
• Drug: Rilvegostomig

Inclusion criteria:

• Participant ≥ 18 year
• ECOG PS of 0 to 1
• Provision of ‘archival’ tumor specimena sample for investigating (e.g. blood, stools, urine, sputum etc.)
• At least one measurable lesion according to RECIST v1.1,
• Minimum life expectancy of 12 weeks
• Adequate and stable cardiac function
• Adequate bone marrowsoft, spongy tissue found in bones that makes blood cells, liver and kidneya pair of bean-shaped organs in the abdomen that are responsible for filtering excess water and waste products from the blood and converting them into urine to be removed from the body function
• Body weight ≥ 35 kg
• Capable of giving signed informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment.

Module 1 specific inclusion criteria:

• Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinomacancer arising from tissues that line organs of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs/gastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC

Module 2 specific inclusion criteria:

• Participants with Stage IV NSCLC Dosethe amount of medication taken Escalation/Backfills
  1. Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapymedication that targets specific molecular features of cancer cells if locally available OR
  2. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.

     Dose Expansion

  1. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.